Skip to main content

Market Overview

Valeant Had A 58% Chance Of Bankruptcy Last Year

Share:
Valeant Had A 58% Chance Of Bankruptcy Last Year

In a new report, Wells Fargo analyst David Maris slams Underperform-rated Valeant Pharmaceuticals Intl Inc (NYSE: VRX) because of a number of unanswered questions surrounding its business and balance sheet. After a horrendous several months, Wells Fargo is bullish on specialty pharmaceutical stocks as a whole, but Valeant is a strong exception.

In his report, Maris uses a balance sheet analysis technique called the Altman Z-score model, which was developed by Edward Altman in the 1960s as a way to measure the probability of bankruptcy.

According to Maris, an Altman Z-score below 1.8 is a signal of financial distress, and Valeant’s Altman Z-score has been below this threshold for each of the last five years. Valeant’s current score is only 0.79, which suggests a bankruptcy probability of 58.4 percent.

“While the Altman Z-score may produce false positives, its predictive accuracy is greater than 70% two years prior to bankruptcy,” Maris explains. “Even so, we consider this ratio as a signal for further questioning.”

Related Link: Market Bull: S&P 500 Could Fall More Than 30%

In addition to Valeant, Wells Fargo used Altman Z-scores to calculate the bankruptcy probabilities of Valeant’s pharma rivals as well. At 39.9 percent, Allergan plc Ordinary Shares (NYSE: AGN) was the only other name with a probability higher than 6.9 percent.

Benzinga reached out to Valeant but no one was available to comment on the report.

Disclosure: the author holds no position in the stocks mentioned.

Latest Ratings for VRX

DateFirmActionFromTo
Jun 2018TD SecuritiesDowngradesBuyHold
Jun 2018BarclaysUpgradesEqual-WeightOverweight
May 2018MizuhoUpgradesNeutralBuy

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

 

Related Articles (AGN + VRX)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech News Short Ideas Health Care Rumors Analyst Ratings Movers Best of Benzinga

Latest Ratings

StockFirmActionPT
FOEGabelli & Co.Downgrades
ACMCredit SuisseMaintains67.0
PRUCredit SuisseMaintains125.0
TDGCredit SuisseMaintains660.0
IIIBarrington ResearchUpgrades7.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com